论文部分内容阅读
目的观察急性冠脉综合征(ACS)发生后24 h内应用不同剂量辛伐他汀的疗效与安全性。方法将117例ACS患者随机分为两组,分别给予辛伐他汀20 mg/d与40 mg/d,每晚1次,用药3个月后观察两组患者血脂达标情况和高敏C-反应蛋白(hs-CRP)及心血管事件的发生率及药物不良反应。结果①两组治疗1、3个月后的总胆固醇、低密度脂蛋白胆固醇、hs-CRP水平均明显降低,且40 mg/d组在各时间段血脂达标情况优于20 mg/d组,住院及随访期间心脏事件发生率也明显减少。②两组均未见不良反应。结论 ACS患者应用20 mg/d及40 mg/d的辛伐他汀均能有效降脂,40 mg/d辛伐他汀调脂及减少心血管事件更佳,且治疗过程中无严重不良反应。
Objective To observe the efficacy and safety of different doses of simvastatin within 24 h after acute coronary syndrome (ACS). Methods A total of 117 patients with ACS were randomly divided into two groups, respectively, simvastatin 20 mg / d and 40 mg / d, once a night, three months after treatment, blood lipid compliance and high-sensitivity C-reactive protein (hs-CRP) and the incidence of cardiovascular events and adverse drug reactions. Results ① The levels of total cholesterol, low density lipoprotein cholesterol, and hs-CRP in both groups were significantly decreased after 1 and 3 months of treatment, and the blood lipid compliance of 40 mg / d group was better than that of 20 mg / d group at each time point The incidence of cardiac events during hospitalization and follow-up was also significantly reduced. ② No adverse reactions in both groups. Conclusions Simvastatin at 20 mg / d and 40 mg / d can be effective in lowering lipid in ACS patients. Simvastatin 40 mg / d can reduce lipid levels and reduce cardiovascular events, and there is no serious adverse reaction during the course of treatment.